Business Wire

O’RIGHT

18.11.2020 10:02:09 CET | Business Wire | Press release

Share
What Makes Taiwanese Beauty Brand O’right Worthy of a Golden Ticket into the Nordics?

As the novel coronavirus spreads across the world, Taiwanese green beauty brand O’right continues to make significant strides in sustainability. This year, O’right made headlines with the opening of its store in Isetan Shinjuku, a leading department store in Japan. Now, the pioneering brand has made its way into Lyko, a Sweden-based beauty and hair care chain that has quickly become the Nordic region’s leading player in the segment. Recently, the green innovator celebrates the Good Design Gold Award (Japan’s Good Design Award is one of the top 4 design awards in the world) honor for its latest innovation – the world’s greenest toothpaste – to offer new green lifestyle solutions worldwide. O’right continues its commitment to doing what’s best for people, the society and earth and calls on businesses and people to follow suit. What started as a small, unknown name in Taiwan has now evolved into a zero carbon beauty brand that is taking the beauty sector by storm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005486/en/

A visionary brand that’s here to stay

O’right and the Swedish beauty retailer Lyko first crossed paths at Cosmoprof Bologna. Founded in the world’s most sustainable country, Lyko partners with brands and stocks products that align with its own values and meets its high standards. O’right has been leading the way to sustainability for years, from its innovative 8 Free standard for creating non-toxic, clean and multi-award-winning range of green products to recently receiving the USDA Certified Biobased Product Label. This year, the company aims to achieve zero carbon (carbon neutrality) for 77 of its products. O’right’s commitment to sustainability is shown not only in its values, but also from product formulations to packaging. The trailblazer demonstrates a positive social and environmental impact and powerful visionary narratives that justify its worth and inspire the Swedish-based chain to wholeheartedly invest in. It’s safe to say that the cosmetic world is excited to watch as the partnership between two companies that share the same values from the East and the West blossoms into something incredible.

Green without borders

Lyko boasts Sweden’s largest e-commerce site with an average monthly traffic count of 4 million visits, along with 37 physical stores in Sweden and Norway. Lyko joins forces with O’right, opening the door for the Taiwanese brand to make its green values and products seen in the Nordic region. O’right green products even made it into the e-commerce platform’s top sellers list. As a green zero carbon brand, O’right believes that the key to making a greater influence in every part of the world is to inspire green living and consumption. When it comes to sustainability, distance and national borders don’t matter.

Does O’right, a small Taiwanese company from the small land of Taiwan, have what it takes to conquer the eco beauty sector of the Nordic region? O’right is determined to show its green value and wow consumers with its holistic green lifestyle solutions and innovative trends.

Link:

ClickThru

Social Media:

https://www.facebook.com/oright.com.tw/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye